The drug developed by the State Scientific Immunology Center uses a unique recumbinant technology. Designed for the prevention and treatment of pollenosis – seasonal allergic reactions. The second stage of clinical studies has been completed at the moment, then the final stage of the research will begin.
Previously, the head of the department said that the observations of the experimental participants have already begun and the preliminary results will be present in June – July 2025. He emphasized that the efficacy of the drug can heal many people who suffer from seasonal porelinosis.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
